Role of favipiravir in the treatment of COVID-19

• Published in: International journal of infectious diseases Vol. 102; pp. 501 - 508
• Main Authors: Joshi, Shashank, Parkar, Jalil, Ansari, Abdul, Vora, Agam, Talwar, Deepak, Tiwaskar, Mangesh, Patil, Saiprasad, Barkate, Hanmant
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.01.2021; The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases; Elsevier
• Subjects: Amides - administration & dosage; Anti-viral; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Clinical guidelines; COVID-19 - drug therapy; COVID-19 - epidemiology; COVID-19 - virology; Humans; In vitro; Pandemics; Pharmacokinetic; Pyrazines - administration & dosage; Review; SARS-CoV-2 - drug effects; SARS-CoV-2 - physiology; Viral clearance; Clinical guidelines; Anti-viral; Viral clearance; In vitro; Pharmacokinetic

•Favipiravir is approved by some countries, including India, for COVID-19 treatment.•Favipiravir has shown rapid viral clearance and faster clinical improvement.•Various treatment recommendations include favipiravir for COVID-19 treatment.•Several ongoing clinical trials will further substantiate fa...